Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ: OLMA · Real-Time Price · USD
13.68
-0.38 (-2.70%)
At close: May 22, 2026, 4:00 PM EDT
13.56
-0.12 (-0.88%)
After-hours: May 22, 2026, 7:25 PM EDT
Olema Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Olema Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $41.82. The average 1-year stock price forecast is 205.70% higher than the current stock price, while the lowest is $23 (+68.13%) and the highest is $62 (+353.22%).
Price Target: $41.82 (+205.70%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Olema Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 6 | 7 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 8 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $38 → $35 | Strong Buy | Maintains | $38 → $35 | +155.85% | May 13, 2026 |
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Mar 27, 2026 |
| Jefferies | Jefferies | Strong Buy Initiates $43 → $40 | Strong Buy | Initiates | $43 → $40 | +192.40% | Mar 19, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $55 → $58 | Buy | Maintains | $55 → $58 | +323.98% | Mar 18, 2026 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $38 → $27 | Strong Buy | Maintains | $38 → $27 | +97.37% | Mar 18, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
23.55M
EPS This Year
-2.27
from -1.87
EPS Next Year
-2.37
from -2.27
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 43.1M | ||||||
| Avg | n/a | 23.6M | ||||||
| Low | n/a | 2.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.00 | -0.97 | |||
| Avg | -2.27 | -2.37 | |||
| Low | -2.70 | -2.98 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.